### ðŸ«  Cardiology: Early Invasive Strategy in Nonâ€“ST-Elevation Acute Coronary Syndrome

#### âœ… True Statements
1. Patients with **nonâ€“ST-elevation acute coronary syndrome (NSTE-ACS)** should undergo **risk stratification** using scoring systems such as the **TIMI** and **GRACE** scores to guide management decisions.
2. An **early invasive strategy** (coronary angiography within 24 hours) is indicated for patients with **high TIMI scores (5â€“7)**, **intermediate TIMI scores (3â€“4)**, or a **GRACE score >140**.
3. A **delayed invasive strategy** (within 72 hours) is appropriate for patients with **intermediate risk** (e.g., **GRACE score 109â€“140**).
4. An **ischemia-guided approach** with **noninvasive stress testing** is appropriate for **low-risk patients** (e.g., **TIMI score <2**, **GRACE score <109**).
5. Patients with **NSTE-ACS** who present with **hemodynamic instability**, **refractory chest pain**, **acute heart failure**, or **ventricular arrhythmias** require **urgent invasive treatment** (within 2 hours).
6. In high-risk patients with **NSTE-ACS**, an **early invasive strategy** improves outcomes such as **death**, **recurrent myocardial infarction (MI)**, and **repeat hospitalization** compared with an ischemia-guided approach.
7. **Thrombolytic therapy** (e.g., **alteplase**) has **no benefit** and is **not recommended** for the treatment of **NSTE-ACS**.
8. **Coronary computed tomography angiography (CCTA)** may be appropriate in patients with suspected **NSTE-ACS**, normal initial **troponin**, and **inconclusive ECG findings**, but it may **delay critical therapy** in high-risk patients.
9. If **percutaneous coronary intervention (PCI)** is performed for NSTE-ACS, **staged PCI** or **culprit plus nonculprit lesion intervention** may be performed based on angiographic findings.

#### ðŸ’¬ Extra
1. TIMI and GRACE scores help predict short-term risk of adverse events such as death or MI.
2. This patient had a **TIMI score of 5** and a **GRACE score of 141**, placing him in the **high-risk category**.
3. Delayed invasive strategy can be safe for patients who do not meet high-risk criteria.
4. Ischemia-guided strategy may include **stress ECG**, **nuclear imaging**, or **CCTA**, typically performed before discharge.
5. These patients represent a critical subgroup where urgent cath may be lifesaving.
6. Data show reduced mortality and morbidity with early revascularization in high-risk NSTE-ACS.
7. Thrombolytics are reserved for ST-elevation MI or cases of NSTE-ACS evolving into STEMI.
8. CCTA is best reserved for low-to-intermediate risk patients when rapid decision-making is not critical.
9. The decision to perform multivessel PCI should be individualized based on clinical stability and lesion complexity.

#### ðŸ”· Tags
#Cardiology #HospitalCare #EmergentCare #PatientOver65

#### ðŸ“™ Reference
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. *JAMA*. 2022;327:662-675. PMID: 35166796 doi:10.1001/jama.2022.0358

#### ðŸ†” Question ID
CVQQQ24012

#### ðŸ•’ Last Updated
June 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Acute Coronary Syndromes, Treatment of Nonâ€“ST-Elevation Acute Coronary Syndromes

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. Patients with **nonâ€“ST-elevation acute coronary syndrome (NSTE-ACS)** should undergo **clinical assessment** and **risk stratification** using **TIMI** and **GRACE** scores to guide invasive treatment decisions.
2. The **TIMI risk score** predicts **14-day rates** of **death**, **recurrent myocardial infarction**, and **urgent revascularization** in **NSTE-ACS**.
3. The **GRACE risk score** predicts **in-hospital** and **postdischarge death and recurrent myocardial infarction**, incorporating **clinical**, **ECG**, and **biomarker** findings.
4. **Urgent invasive treatment (within 2 hours)** is recommended for patients with **type 1 NSTE-ACS** and **hemodynamic instability**, **refractory chest pain**, **acute heart failure**, or **ventricular arrhythmias**.
5. For **high-risk NSTE-ACS** (GRACE >140, elevated **troponin**, new **ST depression**), **early invasive strategy (within 24 hours)** improves clinical outcomes.
6. For **intermediate-risk patients** (e.g., GRACE 109â€“140), a **delayed invasive strategy (within 72 hours)** is appropriate.
7. A **delayed invasive or ischemia-guided approach** is appropriate for **low-risk NSTE-ACS** (TIMI <2, GRACE <109).
8. **Coronary angiography** in **low-risk patients** is typically reserved for those with **ischemia on stress testing** or **persistent angina** despite optimal therapy.
9. **Thrombolytic therapy** is not beneficial and should not be used in **NSTE-ACS**.
10. In **type 2 NSTE-ACS**, **invasive strategies are not indicated**; management focuses on treating the **underlying cause** of increased **myocardial oxygen demand**.
11. The choice between **PCI and coronary artery bypass grafting (CABG)** depends on **coronary anatomy** found during angiography.

#### ðŸ’¬ Extra
1. Clinical variables such as age, risk factors, and ECG findings are key inputs for risk scores.
2. TIMI is simpler but less comprehensive than GRACE.
3. GRACE includes creatinine and troponin levels, which reflect systemic and myocardial risk.
4. These urgent criteria identify patients at imminent risk of clinical deterioration.
5. Studies show reduced death and MI rates with early invasive strategy in stabilized high-risk patients.
6. Intermediate-risk patients can be safely observed while awaiting angiography.
7. Low-risk patients benefit more from an ischemia-guided approach to avoid unnecessary procedures.
8. Stress testing may include **LV function assessment**, **nuclear perfusion**, or **CCTA**.
9. Guidelines consistently recommend against thrombolytics in NSTE-ACS unless transitioning to STEMI.
10. Type 2 MI typically involves **supply-demand mismatch**, such as anemia or sepsis.
11. Revascularization strategy depends on **lesion location**, **complexity**, and **comorbidities**.

#### ðŸ”· Tags
#Cardiology #AcuteCoronarySyndrome #NSTEMI #TIMIScore #GRACEScore #RiskStratification #HospitalCare #EmergentCare

---

#### ðŸ§¾ Supplemental Tables

<!-- TIMI Risk Score Table -->
<table>
  <caption><strong>TIMI Risk Score for Nonâ€“ST-Elevation Acute Coronary Syndromes</strong></caption>
  <thead>
    <tr><th>Prognostic Variables (1 Point Each)</th></tr>
  </thead>
  <tbody>
    <tr><td>Age â‰¥65 y</td></tr>
    <tr><td>â‰¥3 Traditional CAD risk factors<sup>a</sup></td></tr>
    <tr><td>Documented CAD with â‰¥50% diameter stenosis</td></tr>
    <tr><td>ST-segment deviation</td></tr>
    <tr><td>â‰¥2 Anginal episodes in the past 24 h</td></tr>
    <tr><td>Aspirin use in the past week</td></tr>
    <tr><td>Elevated cardiac biomarkers (creatine kinase MB or troponin)</td></tr>
  </tbody>
</table>

<table>
  <thead>
    <tr><th>TIMI Risk Score (Sum of Prognostic Variables)</th><th>Risk</th></tr>
  </thead>
  <tbody>
    <tr><td>0â€“2</td><td>Low risk</td></tr>
    <tr><td>3â€“4</td><td>Intermediate risk</td></tr>
    <tr><td>5â€“7</td><td>High risk</td></tr>
  </tbody>
</table>

<p><em>CAD = coronary artery disease; TIMI = Thrombolysis in Myocardial Infarction.<br>
<sup>a</sup>Hypertension, hypercholesterolemia, diabetes mellitus, being a current smoker, family history of CAD.</em></p>
<p><small>Information from Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. <em>JAMA</em>. 2000;284:835-42. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/10938172">10938172</a> doi:10.1001/jama.284.7.835</small></p>

<!-- Initial Management Figure -->
<figure>
  <img src="Initial Management of NSTE_ACS.svg" alt="Initial Management of Nonâ€“ST-Elevation ACS">
  <figcaption>
    Initial Management of Nonâ€“ST-Elevation Acute Coronary Syndromes (NSTE-ACS) in patients at intermediate or high likelihood of having ACS who are hospitalized for inpatient diagnosis and management.<br>
    Risk stratification after initial therapies includes serial ECG and troponin/myocardial biomarker evaluation and prognostic assessment such as Thrombolysis in Myocardial Infarction (TIMI) or Global Registry of Acute Coronary Events (GRACE) risk scores to guide subsequent intensity of management and timing of invasive assessment with revascularization as indicated. Reappraisal of risk and therapeutic strategy may accompany changes in clinical status or patient preference. <br>
    ACS = acute coronary syndrome; ASA = aspirin; CABG = coronary artery bypass graft surgery; CKD = chronic kidney disease; DM = diabetes mellitus; EF = ejection fraction; MR = mitral regurgitation; PCI = percutaneous coronary intervention; Oâ‚‚ = supplemental oxygen therapy; Oâ‚‚ sat = oxygen saturation; UFH = unfractionated heparin.<br>
    <sup>a</sup>Clopidogrel or ticagrelor may be administered at the time of hospital admission and diagnosis of ACS.<br>
    <sup>b</sup>If coronary artery bypass grafting is required, clopidogrel or ticagrelor should be stopped and surgery may be delayed for 5 days.<br>
    Reprinted from: Amsterdam EA, Wenger NK, Brindis RG, et al. Circulation. 2014;130:2354-94. PMID: 25249586 doi:10.1161/CIR.0000000000000133 and Lawton JS, Tamis-Holland JE, Bangalore S, et al. Circulation. 2022;145:e4-e17. PMID: 34882436 doi:10.1161/CIR.0000000000001039
  </figcaption>
</figure>